Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allstate Corp (ALL) vs TransMedics Group Inc (TMDX) Price & Performance

Allstate CorpTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Allstate Corp vs TransMedics Group Inc — how do they compare? Allstate Corp trades at $257.5 (market cap $66.31B), while TransMedics Group Inc trades at $87.2 (market cap $3.10B). The key difference: Allstate Corp is far larger — about 21.4× TransMedics Group Inc's market cap, and Allstate Corp pays a 1.65% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

ALLTMDX
Market Cap
$66.31B$3.10B
Sector
FinancialsTechnology
52-Week High
$275.11$150.42
52-Week Low
$190.00$61.99
Enterprise Value
$74.96B$3.49B
Dividend Yield
1.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allstate Corp

Allstate (ALL) trades at $256.62, down 4.84% over 24 hours, but maintains a bullish technical signal with strong fundamental performance. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, with revenue growth and improved underwriting profitability. Recent news highlights institutional buying and positive analyst coverage, though some caution exists on sustainability.

The outlook remains positive with a consensus price target of $266.47, offering potential upside. Key risks include sustainability of underwriting margins and macroeconomic sensitivity. Earnings momentum and valuation metrics support a favorable investment case, but investors should monitor competitive pressures and catastrophe loss trends.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.

Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Allstate Corp

On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.

Read more on ALL

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX